Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.

de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK.

J Control Release. 2018 Jan 28;270:158-176. doi: 10.1016/j.jconrel.2017.11.045. Epub 2017 Nov 28.

PMID:
29196043
2.

Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.

Puente P, Fettig N, Luderer MJ, Jin A, Shah S, Muz B, Kapoor V, Goddu SM, Salama NN, Tsien C, Thotala D, Shoghi K, Rogers B, Azab AK.

J Pharm Sci. 2018 Mar;107(3):922-933. doi: 10.1016/j.xphs.2017.10.042. Epub 2017 Nov 21.

3.

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.

Muz B, Azab F, de la Puente P, Landesman Y, Azab AK.

Transl Oncol. 2017 Aug;10(4):632-640. doi: 10.1016/j.tranon.2017.04.010. Epub 2017 Jun 29.

4.

Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.

Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN, Azab AK.

Leuk Lymphoma. 2017 Dec;58(12):2916-2925. doi: 10.1080/10428194.2017.1319052. Epub 2017 May 16.

5.

Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy.

Imai T, Muz B, Yeh CH, Yao J, Zhang R, Azab AK, Wang L.

Cancer Biol Ther. 2017 Feb;18(2):101-105. doi: 10.1080/15384047.2016.1276137. Epub 2017 Jan 3.

6.

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.

Muz B, de la Puente P, Azab F, Azab AK.

Hypoxia (Auckl). 2015 Dec 11;3:83-92. eCollection 2015. Review.

7.

A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma.

Luderer MJ, Muz B, de la Puente P, Chavalmane S, Kapoor V, Marcelo R, Biswas P, Thotala D, Rogers B, Azab AK.

Pharm Res. 2016 Oct;33(10):2530-9. doi: 10.1007/s11095-016-1977-2. Epub 2016 Jul 11.

8.

Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.

de la Puente P, Quan N, Hoo RS, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, Azab AK.

Haematologica. 2016 Jul;101(7):e307-11. doi: 10.3324/haematol.2016.142190. Epub 2016 Apr 14. No abstract available.

9.

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.

de la Puente P, Muz B, Jin A, Azab F, Luderer M, Salama NN, Azab AK.

Blood Cancer J. 2016 Feb 26;6:e399. doi: 10.1038/bcj.2016.7. No abstract available.

10.

Spotlight on ixazomib: potential in the treatment of multiple myeloma.

Muz B, Ghazarian RN, Ou M, Luderer MJ, Kusdono HD, Azab AK.

Drug Des Devel Ther. 2016 Jan 11;10:217-26. doi: 10.2147/DDDT.S93602. eCollection 2016. Review.

11.

A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.

Muz B, de la Puente P, Azab F, Luderer MJ, King J, Vij R, Azab AK.

Br J Haematol. 2016 Apr;173(1):70-81. doi: 10.1111/bjh.13927. Epub 2016 Jan 5.

12.

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib.

Muz B, Azab F, de la Puente P, Rollins S, Alvarez R, Kawar Z, Azab AK.

Biomed Res Int. 2015;2015:417586. doi: 10.1155/2015/417586. Epub 2015 Oct 11.

13.

Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.

de la Puente P, Azab F, Muz B, Luderer M, Arbiser J, Azab AK.

Leuk Lymphoma. 2016 Jul;57(7):1677-86. doi: 10.3109/10428194.2015.1099645. Epub 2015 Nov 16.

14.

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, Melo JV, Griffin JD, Azab AK.

Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30377-5. doi: 10.1016/j.leukres.2015.09.005. [Epub ahead of print]

15.

3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, Achilefu S, Vij R, Azab AK.

Biomaterials. 2015 Dec;73:70-84. doi: 10.1016/j.biomaterials.2015.09.017. Epub 2015 Sep 12.

16.

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells.

Muz B, de la Puente P, Azab F, Luderer M, Azab AK.

Blood Cancer J. 2014 Dec 5;4:e262. doi: 10.1038/bcj.2014.82. No abstract available.

17.

Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.

Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK.

Mol Cancer Res. 2015 Feb;13(2):263-72. doi: 10.1158/1541-7786.MCR-14-0150. Epub 2014 Sep 17.

18.

The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies.

Muz B, de la Puente P, Azab F, Luderer M, Azab AK.

Mol Cancer Res. 2014 Oct;12(10):1347-54. doi: 10.1158/1541-7786.MCR-14-0028. Epub 2014 Aug 26. Review.

19.

The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting.

Lu ZH, Kaliberov S, Zhang J, Muz B, Azab AK, Sohn RE, Kaliberova L, Du Y, Curiel DT, Arbeit JM.

Lab Invest. 2014 Aug;94(8):881-92. doi: 10.1038/labinvest.2014.78. Epub 2014 Jun 23.

20.

Molecularly targeted therapies in multiple myeloma.

de la Puente P, Muz B, Azab F, Luderer M, Azab AK.

Leuk Res Treatment. 2014;2014:976567. doi: 10.1155/2014/976567. Epub 2014 Apr 16. Review.

21.

PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.

Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, Fiala M, Paasch J, Sultana Z, Tyagi A, Abbasi T, Vij R, Azab AK.

Br J Haematol. 2014 Apr;165(1):89-101. doi: 10.1111/bjh.12734. Epub 2014 Jan 9.

PMID:
24405121
22.

Cell trafficking of endothelial progenitor cells in tumor progression.

de la Puente P, Muz B, Azab F, Azab AK.

Clin Cancer Res. 2013 Jul 1;19(13):3360-8. doi: 10.1158/1078-0432.CCR-13-0462. Epub 2013 May 10. Review.

23.

Differential effects of Th1 versus Th2 cytokines in combination with hypoxia on HIFs and angiogenesis in RA.

Larsen H, Muz B, Khong TL, Feldmann M, Paleolog EM.

Arthritis Res Ther. 2012 Aug 6;14(4):R180. doi: 10.1186/ar3934.

24.

Prolyl hydroxylase domain enzyme 2 is the major player in regulating hypoxic responses in rheumatoid arthritis.

Muz B, Larsen H, Madden L, Kiriakidis S, Paleolog EM.

Arthritis Rheum. 2012 Sep;64(9):2856-67. doi: 10.1002/art.34479.

25.

Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis.

Muz B, Khan MN, Kiriakidis S, Paleolog EM.

Arthritis Res Ther. 2009;11(1):201. doi: 10.1186/ar2568. Epub 2009 Jan 20. Review.

26.

Heme oxygenase-1 participates in the anti-inflammatory activity of taurine chloramine.

Muz B, Kontny E, Marcinkiewicz J, Maśliński W.

Amino Acids. 2008 Aug;35(2):397-402. doi: 10.1007/s00726-007-0605-1. Epub 2008 Jan 25.

PMID:
18219551

Supplemental Content

Support Center